OTV2 Octopus Titan Vct Plc

Half-Yearly Results

Octopus Titan VCT plc

Half-Yearly Results

Octopus Titan VCT plc (‘Titan’ or the ‘Company’) announces the half-yearly results for the six months ended 30 June 2023.

Titan’s mission is to invest in the people, ideas and industries that will change the world.

Highlights

	HY2023	HY2022	FY2022
Net assets (£’000)	£1,055,683	£1,180,101	£1,051,760
Loss after tax (£’000)	£(87,609)	£(148,242)	£(319,215)
NAV per share	68.2p	91.3p	76.9p
Total value1	168.2p	186.3p	173.9p
Total return (p)2	(5.7)p	(11.4)p	(23.8)p
Total return %3	(7.4)%	(10.8)%	(22.5)%
Dividends paid in the year	3.0p	3.0p	5.0p
Dividend yield %4	3.9%	2.8%	4.7%
Dividend declared	2.0p	2.0p	3.0p

1. Total value is an alternative performance measure, calculated as NAV plus cumulative dividends paid since launch.
2. Total return is an alternative performance measure, calculated as movement in NAV per share in the period plus dividends paid in the period.
3. Total return % is an alternative performance measure, calculated as total return/opening NAV.
4. Dividend yield is an alternative performance measure, calculated as dividends paid/opening NAV.

Interim Management Report

Chair’s statement

Titan’s total return for the six months to 30 June 2023 was minus 7.4% with net assets at the end of the period totalling £1.1 billion.

The Net Asset Value (NAV) per share at 30 June 2023 was 68.2p which, adjusting for dividends paid of 3.0p per share in May 2023, represents a net decrease of 5.7p per share from 31 December 2022. The total return (NAV plus cumulative dividends paid per share since launch) at the end of the period was 168.2p (31 December 2022: 173.9p). This further decline is, of course, disappointing but reflects the combination of a continuation of the difficult global macro environment and the ongoing readjustment of valuation multiples and funding availability in the early‑stage ventures space since 2021. The Octopus Ventures team are supporting Titan’s portfolio companies through these more challenging times, offering additional resource, expertise or network contacts where relevant. Despite the decrease in NAV, the tax-free annual compound return for the original shareholders since Titan’s launch in October 2007 is 3.9%.

We were pleased to raise over £237 million in our most recent fundraise which closed on 5 April 2023 and, on 26 June 2023, we announced our intention to launch a new offer for subscription later this calendar year. As of 30 June 2023, we had uninvested cash reserves1 of £232.4 million (£179.0 million as at 31 December 2022) to allow us to support our existing portfolio of 140 companies, as well as make new investments in early‑stage, high-growth businesses which we believe embody the objectives of the VCT scheme.

In the six months to 30 June 2023, we utilised £130.7 million of our cash resources, comprising £65.0 million in new and follow-on investments, £34.4 million in dividends (net of the Dividend Reinvestment Scheme), £18.2 million in share buybacks and £13.1 million in investment management fees and other running costs. Together, this utilised 73% of our cash and cash equivalents at 31 December 2022.

DividendsAs shareholders will know, our target to date has been to pay an annual dividend of 5p per share, supplemented by special dividends when appropriate. I am pleased to confirm that the Titan Board has now decided to declare an interim dividend of 2p per share (2022: 2p per share), which will be paid on 21 December 2023 to shareholders on the register as at 1 December 2023.

If you are one of the 26% of shareholders who take advantage of the Dividend Reinvestment Scheme (DRIS), your dividend will be receivable in Titan shares. This is an excellent way to achieve your investment objectives if you prefer the capital value of your investment to grow.

Since inception, we have now paid 100p in tax-free dividends per share, excluding the recently declared dividend.

Following careful consideration of Titan’s dividend policy, the Board are proposing to move from an annual target dividend of 5p per share to an annual target dividend of 5% of NAV, supplemented by special dividends when appropriate.

Principal risks and uncertaintiesThe Board continues to review the risk environment in which Titan operates on a regular basis. There have been no significant changes to the key risks which were described on pages 51 to 54 of the annual report for the year ended 31 December 2022. Given the volatility of the current environment, the Board will continue to evaluate whether there are any significant changes to these risks.

Board of DirectorsFollowing Matt Cooper’s retirement at the Annual General Meeting (AGM) in June 2023, I am pleased to welcome Julie Nahid Rahman who was appointed as a Non‑Executive Director on 1 August 2023. Julie brings to the Board a wealth of experience drawn from her long career in private equity, executive search and strategy consulting.

OutlookOver the period, we have continued to see a readjustment of the early-stage ventures space in which Titan operates. Valuation multiples have continued to reduce from the levels we were seeing in 2022 and there has been a decline in funding availability and exit opportunities.

Companies have been looking to raise smaller amounts at lower company valuations; there has been an intense focus on extending cash runway leading to cost reductions, largely through redundancies; and a significant scale-back of activity by market incumbents, especially growth-stage companies, which has reduced exit opportunities.

The impact of these factors on Titan’s underlying portfolio companies has led to a decline in Titan’s NAV. We recognise this is disappointing, however, we believe the Company is well placed to navigate this turbulent period with the support of shareholders and given the diversity of the underlying portfolio in terms of sector, vintage and stage.

While these conditions are a challenge for existing portfolio companies, they also present opportunities to invest in, and build, new early-stage companies at attractive valuations. Titan can take advantage of this, and our long-term view of early-stage venture capital remains extremely positive.

We also believe that innovation will continue at pace, thanks to the powerful combination of exceptional entrepreneurs, experienced talent and the opportunities created by pain points in many sectors not being appropriately addressed by the status quo. We will continue to strive to back the people, ideas and industries that will change the world.

In the six months to 30 June 2023, Titan invested £65.0 million in new and follow-on opportunities, which brings the total number of companies in the portfolio to 140 at 30 June 2023. The range of both exciting new investments and the upcoming pipeline of opportunities is testament to the work the investment team continue to put into sourcing, securing and working with businesses across all its areas of investment focus. VCTs have long provided a compelling opportunity for UK investors to provide funding for such businesses in a tax‑efficient way, and we look forward to Titan continuing to do so in the future.

I would like to conclude by thanking both the Board and the Octopus team on behalf of all shareholders for their hard work.

Tom Leader Chair

1 The cash reserves include £0.2 million of cash at bank, £127.0 million of money market funds and £105.2 million of corporate bonds as set out in the balance sheet.

Portfolio Manager’s review

Focus on performance

The NAV of 68.2p per share at 30 June 2023 represents a decrease of 5.7p in NAV per share versus a NAV of 76.9p per share as at 31 December 2022 (when adjusted for dividends paid in the period). This decline in NAV is disappointing, however, as shown in the graphs, the long-term opportunity offered by early-stage ventures is still extremely compelling.

The performance over the five years to 30 June 2023 is shown below:

	Year ended 31 October 2018	Period1 ended 31 December 2019	Year ended 31 December 2020	Year ended 31 December 2021	Year ended 31 December 2022	Period ended 30 June 2023
NAV (p)	93.1	95.2	97.0	105.7	76.9	68.2
Cumulative dividends paid (p)	71.0	76.0	81.0	92.0	97.0	100.0
Total value (p)	164.1	171.2	178.0	197.7	173.9	168.2
Total return (%)	1.8	7.6	7.1	20.3	(22.5)	(7.4)
Dividend yield (%)	5.2	5.4	5.3	11.3	4.7	3.9
Equivalent dividend yield for a higher rate tax payer (%)	7.7	8.0	7.8	16.8	7.0	5.9

1. The period to December 2019 was 14 months.

The decrease in NAV over the six-month period has largely been driven by the downward valuation movement of £97.4 million across 76 companies in the now 140-strong portfolio. The drivers of the movement are a combination of factors, including: further market comparable valuation multiple compression; some externally led funding rounds into portfolio companies, which have had dilutive effects on Titan’s shareholding; downward foreign exchange (FX) adjustments in our USD-denominated holdings; and a slowing of growth across the portfolio as companies optimise for efficiency and profitability (where possible). Slowing growth means the typical uplifts in value have been insufficient in this period to offset some of the headwinds mentioned previously.

The most significant portfolio movements have been Big Health, Secret Escapes and ManyPets. Big Health, despite strong underlying performance, has seen its valuation multiple reduced further to reflect the continued softening of comparable digital health company valuations. Secret Escapes has raised further capital at dilutive terms in the context of low availability of capital for growth stage companies. Finally, ManyPets saw a small decline in gross written premium as it took steps to drive higher efficiency and target profitability in the short term, which, given the relative size of the holding, drove a meaningful downward movement in value.

Conversely, 31 companies saw an increase in valuation in the period, delivering a collective increase in valuation of £24.8 million. These valuation increases reflect businesses which have successfully concluded further funding rounds, grown revenues or met certain important milestones. Notable strong performers in the portfolio include Vitesse and Skin+Me, which are both growing strongly and have successfully raised further capital in the period. This further evidences that, even in times of economic decline, there are opportunities available for companies to thrive, and Titan’s diverse portfolio allows multiple avenues to be explored.

The gain on Titan’s uninvested cash reserves was £1.4 million in the six months to 30 June 2023 (31 December 2022: loss of £12.6 million), primarily driven by fair value movements in the corporate bond portfolio and returns on money market funds. The Board’s objective for these investments is to generate sufficient returns through the cycle to cover costs, at limited risk to capital.

ValuationsBelow illustrates the split of valuation methodology (shown as a percentage of portfolio value and number of companies). ‘External price’ includes valuations based on funding rounds that typically completed in the last 12 months to the period end or shortly after the period end, and exits of companies where terms have been issued with an acquirer. ‘External price’ also includes quoted holdings, which are held at their quoted price as at the valuation date. ‘Multiples’ is predominantly used for valuations that are based on a multiple of revenues for portfolio companies. Where there is uncertainty around the potential outcomes available to a company, a probability weighted ‘scenario analysis’ is considered.

Valuation methodology – by value:

• Multiples 57%
• External price 26%
• Scenario analysis 17%

Valuation methodology – by number of companies:

• Multiples 24%
• External price 37%
• Scenario analysis 30%
• Write off 9%

New and follow-on investmentsTitan completed follow-on investments into 12 companies and made 14 new investments in the period. Together, these totalled £65.0 million (made up of £22.7 million invested in the existing portfolio and £42.3 million in new companies). The total value of the portfolio is £819.9 million, as at 30 June 2023.

Below are some examples of new investments made across our seven areas of investment focus during the period. For a full list, please refer to the investment portfolio.

Fintech

• Flock is an insurtech managing general agent (MGA) providing connected insurance for commercial motor fleets.

Health

• Little Journey has created a digital eSupport platform that prepares, informs and provides support for families, healthcare procedures and clinical trials.
• Tympa has developed a novel device and software platform to improve ear and hearing health screening and diagnostics.

B2B software

• Pivotal Future automates and improves the measurement and prediction of biodiversity.
• Secfix automates the preparation for, and the ongoing maintenance of, IT compliance certifications.

Deep tech

• Puraffinity is a smart materials company which has developed a design platform to create materials which can capture the family of ‘forever chemicals’ PFAS (per- and polyfluoroalkyl substances).
• TitanML has created a solution which enables businesses to reduce the processing requirements of high spec artificial intelligence (AI) models quickly and cheaply.

Consumer

• Haiper is developing ground-breaking AI to advance the field of computer graphics.
• Correcto is an AI writing and grammar tool for the Spanish language.

Bio

• Pear Bio is a precision medicine diagnostics and therapeutics discovery company which can recreate a tumour’s microenvironment and assess and monitor the effects of different therapies.

Climate

• Kita is a carbon credit insurance company.

Top 20 investmentsHere we set out the cost and valuation of the top 20 holdings, which account for approximately 57% of the value of the portfolio.

	Company	Investment cost	Total valuation including cost	Investment focus
1	ManyPets	£10.0m	£97.8m	Fintech
2	Skin+Me	£11.5m	£43.3m	Health
3	Amplience	£13.6m	£38.3m	B2B software
4	Permutive	£19.0m	£36.8m	B2B software
5	Orbex	£10.3m	£25.2m	Deep tech
6	Pelago1	£15.9m	£24.6m	Health
7	Token	£12.6m	£18.5m	Fintech
8	Vitesse	£10.1m	£18.1m	Fintech
9	vHive	£8.0m	£17.6m	Deep tech
10	IOVOX	£7.2m	£16.6m	B2B software
11	Sofar	£11.5m	£16.1m	Consumer
12	Legl	£7.3m	£15.8m	B2B software
13	Elliptic	£7.7m	£15.7m	Fintech
14	XYZ	£15.3m	£15.5m	Consumer
15	Big Health	£12.9m	£15.1m	Health
16	Ometria	£11.5m	£12.7m	B2B software
17	Elvie	£6.4m	£11.2m	Health
18	Uniplaces	£9.5m	£10.6m	Consumer
19	Automata	£10.5m	£10.5m	Health
20	Oribiotech	£9.1m	£10.5m	Bio

1. Digital Therapeutics, Inc., formerly Quit Genius, has rebranded as Pelago.

DisposalsIn the period, Arena Flowers (the UK’s number one rated ethical flower delivery company) acquired and merged with portfolio company Patch. As a result, Titan now holds shares in the combined business. The businesses are highly complementary, and the growth potential and synergies create opportunities to deliver value to the stakeholders of the enlarged group.

There have been three disposals made at a loss: Commazero was acquired by Weavr (Paystratus Group Limited); Chronext sold to a Swiss investment group; and By Miles was acquired by private motor insurance Direct Line Group. In aggregate, these disposals generated negligible proceeds compared to an investment cost of £16.2 million.

Unfortunately, having been unsuccessful in securing further funding and having explored and exhausted all available options, ThirdEye was liquidated. The underperformance of a portfolio company is always disappointing for Octopus and shareholders alike, but it is a key characteristic of a venture capital portfolio, and we believe the successful disposals will continue to significantly outweigh the losses over the medium term.

As Titan’s current portfolio continues to mature, we believe that when conditions improve in the future, there should be opportunities for many portfolio companies to take the next step on their growth journey. Successful exits enable Titan to realise the growth a portfolio company has achieved over its investment lifespan.

In the period, Titan also received deferred proceeds from the sale of WaveOptics (to SNAP Inc in 2021) and Conversocial (to Verint Systems Inc in 2021).

The following table shows dividends paid and disposal proceeds over the last five financial years and the current period of 30 June 2023:

	Year ended 31 October 2018	Period1 ended 31December 2019	Year ended 31 December 2020	Year ended 31 December 2021	Year ended 31 December 2022	Period ended 30 June 2023	Total
Dividends (£'000)	24,178	33,187	46,037	101,976	49,596	34,378	289,352
Disposal proceeds2 (£'000)	22,367	26,334	23,915	221,504	62,213	39,960	396,293

1. The period to 31 December 2019 was 14 months.
2. This table includes proceeds received in the period.

VCT qualifying status

Shoosmiths LLP provides both the Board and Octopus with advice concerning ongoing compliance with HMRC rules and regulations concerning VCTs and has advised that Titan continues to be in compliance with the conditions set by HMRC for maintaining approval as a VCT.

As at 30 June 2023, over 92% of the portfolio (as measured by HMRC rules) was invested in VCT-qualifying investments, significantly above the 80% current VCT‑qualifying threshold.

OutlookThe decline in Titan’s NAV is disappointing and is reflective of the rebasing of valuation multiples and funding availability which we have seen over the last year, overlaid with global macroeconomic headwinds. Titan’s unquoted portfolio companies are valued in accordance with UK GAAP accounting standards and the International Private Equity and Venture Capital (IPEV) valuation guidelines. This means we value the portfolio at fair value, which is the price we expect people would be willing to buy or sell an asset for, assuming they had all the information available we do; are knowledgeable parties with no pre-existing relationship; and that the transaction is carried out under the normal course of business. Several of Titan’s portfolio companies have been affected by the challenges the economic backdrop has created, with costs increasing and consumer confidence and spending declining, and valuations have been reappraised in line with all these factors.

More challenging periods, such as these, often bring opportunity and great businesses can be built in times of economic downturn as barriers to adopting new technologies lessen, talent availability improves and there is increased openness to new ways of working. As we continue to meet with extraordinary entrepreneurs and invest in truly disruptive innovation with the support of shareholders, Titan is well placed to take advantage of and navigate these difficult times. Having analysed the portfolio’s projected revenue growth for 2023, we are also forecasting strong collective growth and over 75% of Titan’s portfolio companies have more than 12 months cash runway available to them.

We have seen demand across our areas of focus for the support and expertise offered by our in-house people and talent team as they lean in to help scale and grow the portfolio companies. The team have recently launched new initiatives such as management training and a larger suite of policy documents being made available for portfolio companies to easily adopt, which have been well received. Members of the investment team continue to be thought leaders within their areas of focus too – for example, the health team recently launched their ‘Resilience of Early-stage European Healthtech’ report. This offers a deep dive into the landscape and an analysis of emerging trends set to change the face of healthcare, as well as a guide to regulatory challenges.

The past 18 months have been a period of immense geopolitical and economic change, and Titan has not been immune to the impact of this, with the NAV declining and opportunities to successfully exit companies being less frequent. However, we are reassured by the extraordinary entrepreneurs we continue to meet and invest in, and the drive and passion of our team. We believe this combination will provide Titan with the opportunities it needs for continued success in the future.

Malcolm FergusonPartner and Titan Lead Fund Manager

Directors’ responsibilities statement

The Directors confirm that to the best of their knowledge:

• the half-yearly financial statements have been prepared in accordance with ‘Financial Reporting Standard 104: Interim Financial Reporting’ issued by the Financial Reporting Council;
• the half-yearly financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company; and
• the half-yearly report includes a fair review of the information required by the Financial Services Authority Disclosure and Transparency Rules, being:
  • we have disclosed an indication of the important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;
  • we have disclosed a description of the principal risks and uncertainties for the remaining six months of the year; and
  • we have disclosed a description of related party transactions that have taken place in the first six months of the current financial year, that may have materially affected the financial position or performance of the Company during that period, and any changes in the related party transactions described in the last annual report that could do so.

On behalf of the Board

Tom Leader Chair

Income statement

	Unaudited			Unaudited			Audited
	Six months to 30 June 2023			Six months to 30 June 2022			Year to 31 December 2022
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
	£’000	£’000	£’000	£’000	£’000	£’000	£’000	£’000	£’000
(Loss)/gain on disposal of fixed asset investments	—	(1,922)	(1,922)	—	(472)	(472)	—	66	66
Loss on valuation of fixed asset investments	—	(72,556)	(72,556)	—	(127,603)	(127,603)	—	(284,465)	(284,465)
Gain/(loss) on valuation of current asset investments	—	589	589	—	(11,724)	(11,724)	—	(12,682)	(12,682)
Investment income	1,543	—	1,543	438	—	438	864	—	864
Investment management fees	(522)	(9,917)	(10,439)	(567)	(10,772)	(11,339)	(1,125)	(21,383)	(22,508)
Other expenses	(3,168)	—	(3,168)	(3,527)	—	(3,527)	(7,060)	—	(7,060)
Foreign exchange translation	—	(1,656)	(1,656)	—	5,985	5,985	—	6,570	6,570
Loss before tax	(2,147)	(85,462)	(87,609)	(3,656)	(144,586)	(148,242)	(7,321)	(311,894)	(319,215)
Tax	—	—	—	—	—	—	—	—	—
Loss after tax	(2,147)	(85,462)	(87,609)	(3,656)	(144,586)	(148,242)	(7,321)	(311,894)	(319,215)
Loss per share – basic and diluted (p)	(0.1)	(5.9)	(6.0)	(0.3)	(11.2)	(11.5)	(0.6)	(24.0)	(24.6)

• The ‘Total’ column of this statement is the profit and loss account of the Company; the supplementary revenue return and capital return columns have been prepared under guidance published by the Association of Investment Companies.
• All revenue and capital items in the above statement derive from continuing operations.
• The Company has only one class of business and derives its income from investments made in shares and securities and from bank and money market funds.

Titan has no other comprehensive income for the period.

The accompanying notes form an integral part of the financial statements.

Balance sheet

	Unaudited		Unaudited		Audited
	As at 30 June 2023		As at 30 June 2022		As at 31 December 2022
	£’000	£’000	£’000	£’000	£’000	£’000
Fixed asset investments		819,886		922,316		827,449
Current assets:
Money market funds	127,037		88,297		58,701
Corporate bonds	105,196		104,775		104,244
Applications cash1	338		407		23,299
Cash at bank	228		10,588		16,120
Debtors	4,246		55,310		47,374
		237,045		259,377		249,738
Current liabilities	(1,248)		(1,592)		(25,427)
Net current assets		235,797		257,785		224,311
Net assets		1,055,683		1,180,101		1,051,760
Share capital		1,548		129,209		1,368
Share premium		248,511		212,313		92,896
Capital redemption reserve		52		11,597		27
Special distributable reserve		823,000		585,828		887,288
Capital reserve realised		(65,269)		(21,711)		(53,430)
Capital reserve unrealised		88,667		296,808		160,634
Revenue reserve		(40,826)		(33,943)		(37,023)
Total equity shareholders’ funds		1,055,683		1,180,101		1,051,760
NAV per share (p)		68.2		91.3		76.9

1. Cash held but not yet allotted.

The accompanying notes form an integral part of the financial statements.

The statements were approved by the Directors and authorised for issue on 21 September 2023 and are signed on their behalf by:

Tom Leader ChairCompany Number 06397765

Statement of changes in equity

	Share capital £’000	Share premium £’000	Capital redemption reserve£’000	Special distributable reserve1£’000	Capital reserve realised1 £’000	Capital reserve unrealised £’000	Revenue reserve1 £’000	Total £’000
As at 1 January 2023	1,368	92,896	27	887,288	(53,430)	160,634	(37,023)	1,051,760
Comprehensive income for the period:
Management fees allocated as capital expenditure	—	—	—	—	(9,917)	—	—	(9,917)
Current year loss on disposal of fixed asset investments	—	—	—	—	(1,922)	—	—	(1,922)
Loss on fair value of fixed asset investments	—	—	—	—	—	(72,556)	—	(72,556)
Gain on fair value of current asset investments	—	—	—	—	—	589	—	589
Loss after tax	—	—	—	—	—	—	(2,147)	(2,147)
Foreign exchange translation	—	—	—	—	—	—	(1,656)	(1,656)
Total comprehensive income for the period	—	—	—	—	(11,839)	(71,967)	(3,803)	(87,609)
Contributions by and distributions to owners:
Share issue (includes DRIS)	205	160,895	—	—	—	—	—	161,100
Share issue costs	—	(5,280)	—	—	—	—	—	(5,280)
Repurchase of own shares	(25)	—	25	(18,161)	—	—	—	(18,161)
Dividends paid (includes DRIS)	—	—	—	(46,127)	—	—	—	(46,127)
Total contributions by and distributions to owners	180	155,615	25	(64,288)	—	—	—	91,532
Balance as at 30 June 2023	1,548	248,511	52	823,000	(65,269)	88,667	(40,826)	1,055,683

1. Reserves available for distribution.

	Share capital £’000	Share premium £’000	Capital redemption reserve£’000	Special distributable reserve1£’000	Capital reserve realised1 £’000	Capital reserve unrealised £’000	Revenue reserve1 £’000	Total £’000
As at 1 January 2022	129,850	201,163	9,759	642,873	(14,122)	439,790	(36,272)	1,373,041
Comprehensive income for the period:
Management fees allocated as capital expenditure	—	—	—	—	(10,772)	—	—	(10,772)
Current year loss on disposal of fixed asset investments	—	—	—	—	(472)	—	—	(472)
Loss on fair value of fixed asset investments	—	—	—	—	—	(127,603)	—	(127,603)
Loss on fair value of current asset investments	—	—	—	—	—	(11,724)	—	(11,724)
Loss after tax	—	—	—	—	—	—	(3,656)	(3,656)
Foreign exchange translation	—	—	—	—	—	—	5,985	5,985
Total comprehensive income for the year	—	—	—	—	(11,244)	(139,327)	2,329	(148,242)
Contributions by and distributions to owners:
Share issue (includes DRIS)	1,197	11,204	—	—	—	—	—	12,401
Share issue costs	—	(54)	—	—	—	—	—	(54)
Repurchase of own shares	(1,838)	—	1,838	(18,345)	—	—	—	(18,345)
Dividends paid (includes DRIS)	—	—	—	(38,700)	—	—	—	(38,700)
Total contributions by and distributions to owners	(641)	11,150	1,838	(57,045)	—	—	—	(44,698)
Other movements:
Prior year fixed asset gains now realised	—	—	—	—	3,655	(3,655)	—	—
Total other movements	—	—	—	—	3,655	(3,655)	—	—
Balance as at 30 June 2022	129,209	212,313	11,597	585,828	(21,711)	296,808	(33,943)	1,180,101

1. Reserves available for distribution.

	Share capital £’000	Share premium £’000	Capital redemption reserve£’000	Special distributable reserve1£’000	Capital reserve realised1 £’000	Capital reserve unrealised £’000	Revenue reserve1 £’000	Total £’000
As at 1 January 2022	129,850	201,163	9,759	642,873	(14,122)	439,790	(36,272)	1,373,041
Comprehensive income for the year:
Management fees allocated as capital expenditure	—	—	—	—	(21,383)	—	—	(21,383)
Current year gain on disposal of fixed asset investments	—	—	—	—	66	—	—	66
Loss on fair value of fixed asset investments	—	—	—	—	—	(284,465)	—	(284,465)
Loss on fair value of current asset investments	—	—	—	—	—	(12,682)	—	(12,682)
Loss after tax	—	—	—	—	—	—	(7,321)	(7,321)
Foreign exchange translation	—	—	—	—	—	—	6,570	6,570
Total comprehensive income for the year	—	—	—	—	(21,317)	(297,147)	(751)	(319,215)
Contributions by and distributions to owners:
Share issue (includes DRIS)	1,299	106,307	—	—	—	—	—	107,606
Share issue costs	—	(2,260)	—	—	—	—	—	(2,260)
Repurchase of own shares	(1,864)	—	1,864	(41,192)	—	—	—	(41,192)
Dividends paid (includes DRIS)	—	—	—	(66,220)	—	—	—	(66,220)
Total contributions by and distributions to owners	(565)	104,047	1,864	(107,412)	—	—	—	(2,066)
Other movements:
Share premium cancellation	—	(212,314)	(11,596)	223,910	—	—	—	—
Reduction in the nominal value of share capital	(127,917)	—	—	127,917	—	—	—	—
Prior year fixed asset gains now realised	—	—	—	—	9,575	(9,575)	—	—
Transfer between reserves	—	—	—	—	(27,566)	27,566	—	—
Total other movements	(127,917)	(212,314)	(11,596)	351,827	(17,991)	17,991	—	—
Balance as at 31 December 2022	1,368	92,896	27	887,288	(53,430)	160,634	(37,023)	1,051,760

1. Reserves are available for distribution.

The accompanying notes form an integral part of the financial statements.

Cash flow statement

	Unaudited	Unaudited	Audited
	Six months to	Six months to	Year to
	30 June	30 June	31 December
	2023	2022	2022
	£’000	£’000	£’000
Reconciliation of profit to cash flows from operating activities
Loss before tax	(87,609)	(148,242)	(319,215)
Decrease/(increase) in debtors	1,246	(1,867)	(5,666)
Decrease in creditors	(1,217)	(65,457)	(64,514)
(Gain)/loss on valuation of current asset investments	(589)	11,724	12,682
Loss/(gain) on disposal of fixed asset investments	1,922	472	(66)
Loss on valuation of fixed asset investments	72,556	127,603	284,465
Outflow from operating activities	(13,691)	(75,767)	(92,314)
Cash flows from investing activities
Purchase of current asset investments	(364)	(6,252)	(6,679)
Purchase of fixed asset investments	(64,993)	(77,548)	(156,973)
Sale of fixed asset investments	39,960	32,510	62,213
Outflow from investing activities	(25,397)	(51,290)	(101,439)
Cash flows from financing activities
Application inflows allotted	(22,961)	(2,223)	20,669
Dividends paid (net of DRIS)	(34,378)	(28,945)	(49,596)
Purchase of own shares	(18,161)	(18,345)	(41,192)
Share issues (net of DRIS)	149,351	2,593	90,982
Share issues costs	(5,280)	(1)	(2,260)
Inflow/(outflow) from financing activities	68,571	(46,921)	18,603
Increase/(decrease) in cash and cash equivalents	29,483	(173,978)	(175,150)
Opening cash and cash equivalents	98,120	273,270	273,270
Closing cash and cash equivalents	127,603	99,292	98,120
Cash and cash equivalents comprise of:
Cash at bank	228	10,588	16,120
Applications cash	338	407	23,299
Money market funds	127,037	88,297	58,701
Closing cash and cash equivalents	127,603	99,292	98,120

Condensed notes to the half-yearly report

1. Basis of preparation

The unaudited half-yearly results which cover the six months to 30 June 2023 have been prepared in accordance with the Financial Reporting Council’s (FRC) Financial Reporting Standard 104 Interim Financial Reporting (March 2018) and the Statement of Recommended Practice (SORP) for Investment Companies re-issued by the Association of Investment Companies in July 2022.

2. Publication of non-statutory accounts

The unaudited half-yearly results for the six months ended 30 June 2023 do not constitute statutory accounts within the meaning of Section 415 of the Companies Act 2006 and have not been delivered to the Registrar of Companies. The comparative figures for the year ended 31 December 2022 have been extracted from the audited financial statements for that year, which have been delivered to the Registrar of Companies. The independent auditor’s report on those financial statements, in accordance with chapter 3, part 16 of the Companies Act 2006, was unqualified. This half-yearly report has not been reviewed by the Company’s auditor.

3. Earnings per share

The loss per share is based on 1,458,917,593 Ordinary shares (30 June 2022: 1,293,940,509 and 31 December 2022: 1,297,081,006), being the weighted average number of shares in issue during the period. There are no potentially dilutive capital instruments in issue and so no diluted returns per share figures are relevant. The basic and diluted earnings per share are therefore identical.

4. Net asset value per share

	30 June	30 June	31 December
	2023	2022	2022
Net assets (£’000)	1,055,683	1,180,101	1,051,760
Ordinary shares in issue	1,547,797,287	1,292,086,596	1,367,949,929
Net asset value per share	68.2p	91.3p	76.9p

5. Dividends

The interim dividend declared of 2.0p per share for the six months ending 30 June 2023 will be paid on 21 December 2023 to those shareholders on the register as at 1 December 2023.

On 24 May 2023, a 3.0p second interim dividend relating to the 2022 financial year was paid.

6. Buybacks and allotments

During the six months to 30 June 2023, the Company bought back 24,948,066 Ordinary shares at a weighted average price of 72.8p per share (six months ended 30 June 2022: 18,378,101 Ordinary shares at a weighted average price of 99.8p per share; year ended 31 December 2022: 45,009,970 Ordinary shares at a weighted average price of 92.9p per share).

During the six months to 30 June 2023, 204,539,959 shares were issued at a weighted average price of 81.0p per share (six months ended 30 June 2022: 11,966,301 shares at a weighted average price of 104.6p per share; year ended 31 December 2022: 114,461,503 shares at a weighted average price of 96.9p per share).

7. Related party transactions

Octopus acts as the Portfolio Manager of the Company. Under the management agreement, Octopus receives a fee of 2.0% per annum of the net assets of the Company for the investment management services, but in respect of funds raised by the Company under the 2018 Offer and thereafter (and subject to the Company having a cash reserve of 10% of its NAV), the annual management charge on uninvested cash will be the lower of either (i) the actual return that the Company receives on its cash and funds that are the equivalent of cash subject to a 0% floor and (ii) 2%. During the period, the Company incurred management fees of £10,439,000 payable to Octopus (30 June 2022: £11,339,000; 31 December 2022: £22,508,000), which were fully settled by 30 June 2023.

Octopus provides non-investment services to the Company and receives a fee for these services which is capped at the lower of (i) 0.3% per annum of the Company’s NAV or (ii) the administration and accounting costs of the Company for the year ended 31 December 2020 with inflation increases in line with the Consumer Price Index. During the period, the Company incurred non-investment services fees of £1,046,000 payable to Octopus (30 June 2022: £921,600; 31 December 2022: £1,893,000), which were fully settled by 30 June 2023.

In addition, Octopus is entitled to performance-related incentive fees. The incentive fee arrangements were designed to make sure that there were significant tax-free dividend payments made to shareholders as well as strong performance in terms of capital and income growth, before any performance-related fee payment was made. There were no performance fees accrued for the six months to 30 June 2023 (30 June 2022: £nil; 31 December 2022: £nil).

Octopus received £0.02 million in the six months to 30 June 2023 (six months ended 30 June 2022: £0.03 million; year ended 31 December 2022: £nil) in regard to arrangement and monitoring fees in relation to investments made by the Company.

Titan owns Zenith Holding Company Limited, which owns a share in Zenith LP, a fund managed by Octopus.

In the period, Octopus Investments Nominees Limited (OINL) purchased Titan shares from shareholders to correct administrative issues, with the intention that the shares will be sold back to Titan in subsequent share buybacks. As at 30 June 2023, no Titan shares were held by OINL (30 June 2022: 570 shares; 31 December 2022: nil shares) as beneficial owner. Throughout the period to 30 June 2023, OINL purchased 1,602,591 shares (30 June 2022: 283,737; 31 December 2022: 729,365 shares) at a cost of £1,372,000 (30 June 2022: £288,000; 31 December 2022: £678,000) and sold 1,602,591 shares (30 June 2022: 286,135; 31 December 2022: 737,002 shares) for proceeds of £1,171,000 (30 June 2022: £291,000; 31 December 2022: £672,000). This is classed as a related party transaction as Octopus, the Portfolio Manager, and OINL are part of the same group of companies. Any such future transactions, where OINL takes over the legal and beneficial ownership of Company shares, will be announced to the market and disclosed in annual and half-yearly reports.

Several members of the Octopus investment team hold non-executive directorships as part of their monitoring roles in Titan’s portfolio companies, but they have no controlling interests in those companies.

The Directors received the following dividends from Titan:

	Period to	Period to	Year to
	30 June	30 June	31 December
	2023	2022	2022
Tom Leader (Chair)	1,625	692	1,640
Matt Cooper1	70,597	63,103	117,661
Jane O'Riordan	4,428	3,408	6,530
Lord Rockley	2,126	575	2,145
Gaenor Bagley	733	267	740

1. Matt Cooper stepped down as a Director on 14 June 2023.

8. Voting rights and equity management

The following table shows the percentage voting rights held by Titan of each of the top ten investments held in Titan, on a fully diluted basis.

	% voting rights
Investments	held by Titan
Many Group Limited (trading as ManyPets)	7.5%
Mr & Mrs Oliver Ltd (trading as Skin+Me)	20.6%
Amplience Limited	21.0%
Permutive Inc.	17.9%
Orbital Express Launch Limited (trading as Orbex)	10.8%
Digital Therapeutics (trading as Pelago, formerly Quit Genius)	16.6%
Token.IO Ltd	13.5%
Vitesse PSP Ltd	15.4%
vHive Tech Ltd	19.0%
Iovox Limited	29.4%

9. Post balance sheet eventsThe following events occurred between the balance sheet date and the signing of this half‑yearly report:

• four new investments completed totalling £4.1 million;
• three follow-on investments completed totalling £9.8 million; and
• a final order to cancel share premium amounting to £248.5 million was granted on 1 August 2023.

10. Half-Yearly Report

The unaudited half-yearly report for the six months ended 30 June 2023 will shortly be available to view at octopustitanvct.com.

For further information please contact:

Rachel Peat  Octopus Company Secretarial Services LimitedTel: +44 (0)80 0316 2067

LEI: 213800A67IKGG6PVYW75